Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Laurence B. McCullough, PhD, Frank A. Chervenak, MD, and John H. Coverdale, MD, MEd
The best interests of a pregnant psychotic patient can be served by determining her decision making capacity and using surrogate decision making if needed.
AMA J Ethics. 2016;18(3):209-214. doi:
10.1001/journalofethics.2016.18.3.ecas2-1603.
Because health systems with high-functioning primary care services have decreased mortality and improved health outcomes, the sector can be classified as a public good, like police and fire services and public education.
AMA J Ethics. 2015;17(7):637-646. doi:
10.1001/journalofethics.2015.17.7.stas1-1507.
Given full information about the risks of long-term opioid therapy, patients often see the value of exploring other options rather than thinking their physicians are reluctant to prescribe narcotics for fear of litigation or regulatory action.
AMA J Ethics. 2015;17(3):202-208. doi:
10.1001/journalofethics.2015.17.3.ecas1-1503.
To help a seriously ill young patient whose normal childhood has been disrupted, pediatricians must be more than sympathetic professionals in white coats—they must know how to motivate each patient and then go the extra mile to do so.
AMA J Ethics. 2015;17(5):461-464. doi:
10.1001/journalofethics.2015.17.5.msoc1-1505.
Using data from comparative effectiveness studies to inform cost-effectiveness analyses or other economic evaluations would strengthen ethical policy making.
AMA J Ethics. 2015;17(7):651-655. doi:
10.1001/journalofethics.2015.17.7.pfor1-1507.